Baseline Integrase Resistance Testing in HIV Newly Diagnosed Patients: Shall We Revisit The Clinical Significance?

Webinar on How Sanger vs Next-Generation Sequencing for Drug Resistance Mutations Detection

Integrase strand transfer inhibitor (INSTI)-based regimens have become recommended for initial treatment of most HIV patients. The guidelines for HIV drug resistance testing for anti-retroviral naïve HIV patients include testing for mutations in the Reverse Transcriptase (RT) and Protease (PR) regions of the pol gene. Resistance mutation screening of the Integrase (IN) region is currently recommended if INSTI transmitted resistance is a concern or in patients experiencing viremia while on INSTI-based regimens. This presentation will discuss the clinical significance of baseline IN resistance testing, especially with the current availability of the first FDA-authorized assay that consolidates the resistance testing of RT, PR, and IN regions.


Dr. Heba Mostafa

Assistant Professor of Pathology, DIrector of the Molecular Virology Laboratory.
Johns Hopkins School of Medicine.

Dr. Heba Mostafa completed her M.D. at the Faculty of Medicine, Alexandria University, Egypt.  She then moved to the United States where she earned her Ph.D. in Microbiology at the University of Kansas followed by three years of Post-Doctoral Research Fellowship at St. Jude Children’s Research Hospital.  Dr. Mostafa completed a CPEP Clinical Microbiology Fellowship at the University of Rochester Medical Center and earned her ABMM certification.  Dr. Mostafa is currently an Assistant Professor of Pathology and the Director of the Molecular Virology Laboratory at Johns Hopkins School of Medicine.

Register here

Webinar on How Sanger vs Next-Generation Sequencing for Drug Resistance Mutations Detection Affects HIV Treatment Choice

How Sanger vs Next-Generation Sequencing for Drug Resistance Mutations Detection

Join us in the presentation of how NGS can give you more information on drug resistance information that will affect HIV treatment choice. We will discuss the advantages of NGS DRM identification over Sanger methods. Also, take this chance to learn more about the recent FDA-authorized Sentosa SQ HIV-1 Genotyping Assay, and how it can be easily implemented in your lab.


Ravindra Kolhe M.D, Ph.D.
Director, Georgia Esoteric & Molecular Laboratory, Medical College of Georgia, Augusta University

Currently, Dr. Kolhe is a Vice Chairman in the Department of pathology at the Augusta University, Augusta GA, and divides his time between directing Molecular Pathology, Cytogenetics, Breast Pathology, teaching and research. He is the CLIA laboratory director for the Georgia Esoteric & Molecular Labs and also serves as the Medical Director for the Cytogenetics Laboratory.

Register here